#KRASmt - Twitter Hashtag

almost 4 years ago

Day 2 @etop_ibcsg Annual Meeting, @DrJNaidoo 🇮🇪 presents an update on the #KRASmt #ADDEPT trial @IrishLungCancer @LungCommunity @CancerCentreIre @cancertrials_ie #LCSM

MartinBarr10's tweet photo. Day 2 @etop_ibcsg Annual Meeting, @DrJNaidoo 🇮🇪 presents an update on the #KRASmt #ADDEPT trial @IrishLungCancer @LungCommunity @CancerCentreIre @cancertrials_ie #LCSM https://t.co/HCx9V2fkgu

0

17

2

0

Charu Aggarwal, MD, MPH, FASCO

@CharuAggarwalMD

over 5 years ago

Important to highlight that this approval is for 2L therapy for #KRASMT #NSCLC. Immunotherapy is associated w/ significant benefit in 1L especially for PDL1 >50% and should not be discounted based on this new approval #LCSM Our @JAMAOnc paper👉 https://t.co/VJxMrsmwbc

Toni Choueiri, MD

@DrChoueiri

over 5 years ago

JUST IN: @US_FDA approves 1st Targeted Therapy for NSCLC with KRAS G12C. 1st approved KRAS mutation therapy ever (25% of NSCLC mutations; 13% KRAS G12C) @OncoAlert https://t.co/XRgcynmAw2

DrChoueiri's tweet photo. JUST IN: @US_FDA approves 1st Targeted Therapy for NSCLC with KRAS G12C. 1st approved KRAS mutation therapy ever (25% of NSCLC mutations; 13% KRAS G12C) @OncoAlert

https://t.co/XRgcynmAw2 https://t.co/kW5gJRDqVk

2

164

52

2

0

8

1

0

Charu Aggarwal, MD, MPH, FASCO

@CharuAggarwalMD

over 5 years ago

In patients with a #KRASMT, outcomes with chemo+IO and IO were similar, 21.1 vs 20 months leading us to conclude that these patients do as well with either approach #LCSM #Immunotherapy

CharuAggarwalMD's tweet photo. In patients with a #KRASMT, outcomes with chemo+IO and IO were similar, 21.1 vs 20 months leading us to conclude that these patients do as well with either approach #LCSM #Immunotherapy https://t.co/JhDfg5xDds

1

4

0

Charu Aggarwal, MD, MPH, FASCO

@CharuAggarwalMD

over 6 years ago

STK11 & KEAP1 MT in #NSCLC pts receiving #Pembro on #KN42. Authors conclude that IO was superior to chemo in these subsets. Imp' to note: 1. #KRASMT not reported 2. How do these pts do with chemo+IO? 3. Overall prevalence of these MT seem low #AACR20 @AACR #LCSM @OncoAlert

CharuAggarwalMD's tweet photo. STK11 & KEAP1 MT in #NSCLC pts receiving #Pembro on #KN42. Authors conclude that IO was superior to chemo in these subsets. Imp' to note:
1. #KRASMT not reported
2. How do these pts do with chemo+IO?
3. Overall prevalence of these MT seem low
#AACR20 @AACR #LCSM @OncoAlert https://t.co/FRCZqybOP8

2

31

12

4

0

Top Tweets for #KRASmt

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users